| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1950-01-17 |
| Identifiers | MRN HR-EN004-SYN; SSN (made up) 000-04-3318 |
| Document date | 2026-03-30 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week gout and blood pressure review; urology consultation today. [S]
Mr. Franklin returns four weeks after starting allopurinol 100 mg and colchicine 0.6 mg daily and changing hydrochlorothiazide to losartan 50 mg. He has had no gout flare, no rash, and no diarrhea. His home blood pressure averages 136/80. He still has an interrupted stream, pain at the end of voiding, and pink urine after car journeys, and he gets up three times a night. He takes acetaminophen for the bladder pain about twice a week and no ibuprofen. He is drinking more water, about 1.5 L a day, and has cut back to one glass of wine with dinner. He saw the urologist this morning. [S]
| Element | Detail |
|---|---|
| Gout | No flare since starting allopurinol and colchicine |
| Medication tolerance | No rash, diarrhea, or muscle aches |
| Home blood pressure | Average 136/80 mmHg on losartan |
| Urinary symptoms | Interrupted stream, terminal pain, pink urine after car journeys; nocturia three times |
| Fluids and diet | About 1.5 L of water a day; one glass of wine with dinner |
| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No joint pain or swelling |
| Genitourinary | Positive | Interrupted stream, terminal dysuria, intermittent pink urine, nocturia three times |
| Integumentary | Negative | No rash or itching on allopurinol |
| Gastrointestinal | Negative | No diarrhea or nausea on colchicine |
| Neurological | Negative | No dizziness on standing |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2019-05-06 to 2026-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-03-30 | completed | S |
| Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily | Two tablets by mouth daily | Oral route | 2026-03-30 to 2026-05-18 | completed | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-03-02 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery | One capsule by mouth at bedtime | Oral route | 2026-03-30 to 2026-04-20 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-30 | Body height | 175 | cm | S |
| 2026-03-30 | Body weight | 95.4 | kg | S |
| 2026-03-30 | Body mass index (BMI) [Ratio] | 31.2 | kg/m2 | S |
| 2026-03-30 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-03-30 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-30 | Heart rate | 70 | /min | S |
| 2026-03-30 | Respiratory rate | 16 | /min | S |
| 2026-03-30 | Body temperature | 36.6 | Cel | S |
| 2026-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-30 | Urate [Mass/volume] in Serum or Plasma | 7.6 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-03-30 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-30 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-30 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-30 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.34 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 55 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-03-30 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-30 | US Urinary bladder Volume post void | 160 | mL | <=100 mL | High | S |
| 2026-03-30 | Maximum Urine flow by Uroflowmetry | 8.5 | mL/s | >=10 mL/s | Low | S |
| 2026-03-30 | International Prostate Symptom Score [IPSS] | 16 | {score} | S |
Vital signs recorded on 2026-03-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, comfortable |
| Joints | No synovitis; no tophi; right first toe joint normal |
| Abdomen | Mild suprapubic tenderness; bladder not palpable |
| Cardiovascular | Regular rhythm; no edema |
| Skin | No rash |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |
| Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection | active | confirmed | N40.1 | S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum urate | Every 2 to 5 weeks while titrating; every 6 months once at target | Completed today | 7.6 mg/dL four weeks after starting allopurinol 100 mg; dose increased |
| Medication safety | Allopurinol hypersensitivity and colchicine tolerance | Every visit while titrating | Completed today | No rash, fever, diarrhea, or muscle symptoms |
| Laboratory | HLA-B*58:01 before allopurinol | Once, only in Southeast Asian or African American patients | Not indicated | Not of Southeast Asian or African ancestry |
| Medication safety | Flare prophylaxis | 3 to 6 months after starting urate-lowering therapy | Completed today | Colchicine 0.6 mg daily, week 4 |
| Laboratory | Potassium and creatinine 2 to 4 weeks after starting an ARB | Once after starting or titrating | Completed today | Potassium 4.4 mmol/L, creatinine 1.34 mg/dL, eGFR 55, four weeks after starting losartan |
| Examination | Office and home blood pressure | Every visit | Completed today | 138/80 mmHg in the office; home average 136/80 |
| Medication safety | Medication review for NSAIDs and dose adjustment for kidney function | Every visit | Completed today | No NSAIDs; allopurinol and colchicine doses suit eGFR 55 |
| Survey | IPSS | Baseline and every follow-up visit | Completed today | 16, moderate |
| Examination | Uroflowmetry and post-void residual | Before a procedure or when obstruction is suspected | Completed today | Maximum flow 8.5 mL/s; residual 160 mL |
| Referral | Urology evaluation of the bladder stone and hematuria | At diagnosis | Completed today | Seen today; cystoscopy shows no tumor; surgery booked |
| Laboratory | PSA | Only if it would change management | Not indicated | Age 76; it would not change the planned surgery, and resected tissue will be examined |
| Self-management | Fluid intake for stone prevention | Every visit | Completed today | About 1.5 L a day; goal 2.5 to 3 L |
| Self-management | Diet and alcohol for gout | Every visit | Completed today | Wine cut to one glass with dinner; fewer rich meals |
Goal progress:
Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026)
Follow-up: Surgery in three weeks. Review four weeks after surgery with serum urate, a metabolic panel, urine tests, and a 24-hour urine collection. Next scheduled visit 2026-05-18: review four weeks after stone removal and prostate resection, with urate titration and stone metabolic evaluation. [S]